Lanadelumab is under clinical development by Takeda Pharmaceutical and currently in Phase III for Angioedema. According to GlobalData, Phase III drugs for Angioedema have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Lanadelumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lanadelumab (Takhzyro) recombinant, fully human, monoclonal antibody (IgG1/ κ -light chain) produced in Chinese Hamster Ovary (CHO) cells. It is formulated as injectable solution for subcutaneous route of administration. Takhzyro is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients of 12 years and older.
Lanadelumab (DX-2930, SHP643, TAK-743) is under development for the prophylactic treatment of Coronavirus disease 2019 (COVID-19), plasma kallikrein (bradykinin) mediated Hereditary Angioedema (HAE). The therapeutic candidate is administered as subcutaneous and intravenous injection. It is a fully human monoclonal antibody acts by targeting plasma kallikrein. It was also under development for diabetic macular edema and Coronavirus disease 2019 (COVID-19) pneumonia, factor XII-associated cold autoinflammatory syndrome (FACAS).
Takeda Pharmaceutical overview
Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China, India, and Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.
For a complete picture of Lanadelumab’s drug-specific PTSR and LoA scores, buy the report here.